Overview

Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and clinical activity of ASM-024 administered as a dry powder for inhalation formulation to patients with GOLD 2 or GOLD 3 COPD.
Phase:
Phase 2
Details
Lead Sponsor:
Asmacure Ltée